BridgeBio Oncology Therapeutics, Inc. financial data

Symbol
BBOT on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1210% % 45%
Debt-to-equity 21% %
Return On Equity -125% % -356%
Return On Assets -40% % 0.12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80,032,823 shares
Common Stock, Shares, Outstanding 79,991,768 shares 281412%
Entity Public Float $465,152,172 USD 184%
Common Stock, Value, Issued $8,000 USD
Weighted Average Number of Shares Outstanding, Basic 79,987,399 shares 337%
Weighted Average Number of Shares Outstanding, Diluted 79,987,399 shares 337%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $38,074,000 USD 95%
General and Administrative Expense $23,006,034 USD 431%
Operating Income (Loss) $96,132,034 USD -130%
Nonoperating Income (Expense) $13,008,952 USD 61%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $134,044,000 USD -80%
Earnings Per Share, Basic -490 USD/shares 54%
Earnings Per Share, Diluted -490 USD/shares 54%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $373,687,000 USD 1111%
Marketable Securities, Current $51,773,000 USD -59%
Cash, Cash Equivalents, and Short-term Investments $425,500,000 USD
Assets, Current $432,396,000 USD 172%
Property, Plant and Equipment, Net $956,000 USD 95%
Operating Lease, Right-of-Use Asset $2,330,000 USD
Other Assets, Noncurrent $12,567,000 USD 152%
Assets $448,381,000 USD 173%
Accounts Payable, Current $1,374,000 USD -55%
Accrued Liabilities, Current $1,783,561 USD 7544%
Liabilities, Current $35,041,000 USD 79%
Operating Lease, Liability, Noncurrent $2,244,000 USD
Liabilities $37,285,000 USD 90%
Accumulated Other Comprehensive Income (Loss), Net of Tax $16,000 USD -95%
Retained Earnings (Accumulated Deficit) $356,567,000 USD -60%
Stockholders' Equity Attributable to Parent $411,096,000 USD
Liabilities and Equity $448,381,000 USD 173%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $734,642 USD -19%
Common Stock, Shares Authorized 500,000,000 shares 1109%
Common Stock, Shares, Issued 79,991,768 shares 281412%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $373,819,000 USD 1107%
Deferred Tax Assets, Valuation Allowance $87,182,000 USD 93%
Deferred Tax Assets, Gross $87,882,000 USD 1845%
Operating Lease, Liability $2,766,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $44,772,000 USD -171%
Lessee, Operating Lease, Liability, to be Paid $3,235,000 USD
Operating Lease, Liability, Current $522,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $730,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $705,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.074 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $469,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $755,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $42,732,000 USD 212%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Unrecognized Tax Benefits $2,164,000 USD 65%
Lessee, Operating Lease, Liability, to be Paid, Year Four $782,000 USD
Additional Paid in Capital $767,639,000 USD 1663%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $700,000 USD 6264%
Share-based Payment Arrangement, Expense $1,425,000 USD 86%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%